The emergence of COVID-19 has prompted rapid investigation of potential therapeutic options. Some early candidates have included chloroquine, hydroxychloroquine, azithromycin, lopinavir/ritonavir, remdesivir, ribavirin, and others. Some of these are known to pose a risk of ventricular arrhythmia. With an uncertain degree of potential for benefit, an assessment of risk of therapy should be undertaken. During the pandemic, avoidance of nonessential testing, including electrocardiography (ECG), reduces exposure of health care workers and other patients to infectious risk and is therefore recommended when possible.[@bib1] An expert writing group of members of the Canadian Heart Rhythm Society was selected to derive a set of consensus-based recommendations to guide clinicians. This report was approved by the board of the Canadian Heart Rhythm Society; a fully referenced version is available as [Supplementary Material](#appsec1){ref-type="sec"}.

It should be noted that the advice included here is offered during a health care crisis when access to some medical tests may increase population infection risk, the potential for benefit of these drugs is unknown, and there are no treatments with clear efficacy beyond supportive care. These recommendations should be reevaluated when these factors change.

Chloroquine and Hydroxychloroquine {#sec1}
==================================

The current data supporting the use of chloroquine or hydroxychloroquine for treatment of infection with SARS-CoV-2 includes evidence of *in vitro* activity against SARS-CoV-2 and limited evidence from noncomparative clinical research. Clinical trial results from China[@bib2] had not yet been published in peer-reviewed form at the time of writing, and data from France[@bib3] are useful but preliminary. The French study was nonrandomized, and the preliminary report included only viral RNA detection from nasopharyngeal swabs as its primary end point rather than clinical outcomes. Although limited, the data have been sufficient to prompt recommendations for treatment from national agencies in China and Italy. The overall safety of these drugs has been established over several decades of use, with good cardiovascular safety profiles in small studies. However, cases of QT interval prolongation and torsade de pointes (TdP) have been reported. Larger cohort studies have focused on the low risk of retinopathy associated with chronic administration. Rare cases of cardiomyopathy, atrioventricular block, and bundle branch block have been reported during both acute and chronic administration.

Azithromycin {#sec2}
============

Azithromycin has been suggested to have *in vitro* antiviral activity and is effective in treating bacterial pneumonia. In the French series,[@bib3] 6 patients were treated with azithromycin in addition to hydroxychloroquine and had further reductions in detectable viral load. Azithromycin is known to have an increased risk of QT interval prolongation, TdP, and sudden cardiac death, but the absolute risk is small and it has been used safely in clinical practice without routine ECG-based QT interval surveillance.

Lopinavir/Ritonavir {#sec3}
===================

Lopinavir is a protease inhibitor developed to treat human immunodeficiency virus infection, often combined with ritonavir, which prolongs its plasma half-life, and was shown to have *in vitro* as well as clinical activity against SARS-CoV and *in vitro* activity against MERS-CoV. It has been evaluated in small observational series and has been tested in a prospective randomized controlled trial against COVID-19 for patients with radiographic evidence of pneumonia and impaired oxygen exchange, in which it did not demonstrate a measurable improvement in the clinical course.[@bib4]

Combinations of Drugs {#sec4}
=====================

Data regarding combinations of drugs used to treat COVID-19 are insufficient to draw reliable conclusions about the safety of this approach. It is important to note that combining more than one proarrhythmic medication is known to increase the risk of significant QT interval prolongation; however, the risk of medication-induced TdP is quite variable, with an incidence that ranges from 0.001% to 8% depending on the medications used.

Other Candidate Drugs {#sec5}
=====================

Other drugs that are being investigated for activity to treat COVID-19 include remdesivir, favipiravir, ribavirin, sarilumab, and baricitinib, for which limited data are available regarding effects on cardiac arrhythmias.

Patients With Higher Clinical Risk {#sec6}
==================================

Some patients may be at elevated clinical risk for drug-induced ventricular arrhythmia. Patients with inherited long QT syndrome are known to be at increased risk. Expert opinion may be helpful in determining how best to mitigate risk for patients with prolonged baseline corrected QT interval (QTc) who have COVID-19. The use of other drugs or medical conditions that may prolong the QT interval or otherwise interact with these medications may increase risk of adverse events. Drug-induced prolongation of the QT interval in vulnerable patients may be exacerbated in older patients, by coexistent cardiac conditions such as cardiomyopathy, ischemia, heart failure, or bradycardia, and by other conditions such as diabetes, electrolyte abnormalities, hypoglycemia, or renal failure. It is possible that severe cases of COVID-19 would be more vulnerable to QT interval prolongation as well. It is likely that patients at higher clinical risk of drug-induced arrhythmia would also be at higher risk for more severe infectious complications and are more likely to be treated as inpatients, in which case ECG monitoring would more likely be indicated for supportive medical care. This is reflected in the recommendations below.

Putting Arrhythmic Risk in Context {#sec7}
==================================

The anticipated risk of life-threatening arrhythmia from the medications included here is likely to be low, while the potential for benefit remains uncertain. Methods to mitigate risk are warranted, but should not impose undue increased risk of infection to other patients or health care workers, or undue increase in demand on medical resources during a time of crisis with potential restrictions on access to personal protective equipment, drug therapy, and even care providers.[@bib1] If COVID-19 antimicrobial drugs reduce mortality rate by even 5%, it is likely that this would constitute a substantial net benefit compared with the risk of drug-induced sudden death, recognizing that the absolute levels of risk and benefit are unclear at present. Clinical risk scores may be useful in minimizing risk, but ultimately, the decision whether to require extra testing and monitoring will require balancing of potential individual benefit against the risk of individual and population harm. This includes the local prevalence of COVID-19 infection and associated risk of subjecting patients to important, albeit discretionary, testing such as ECG. It is recognized that assessment of the balance of risks may differ in different jurisdictions.

Alternate Testing Methods {#sec8}
=========================

Single-use or easily sterilized hand-held cardiac rhythm monitoring devices have become increasingly available and may permit reliable recording of cardiac intervals. Availability of such means to perform these recordings may obviate the need for obtaining a standard 12-lead ECG and may not pose an infectious risk. If available, they may be used to confirm a patient's risk status before initiation of antimicrobial therapy and may reduce personal risk without a meaningful increase in concomitant population risk.

Recommendations {#sec9}
===============

The use of medications with unproven benefit for treatment of COVID-19 should primarily focus on robust evaluation within a clinical trial whenever possible. We recommend that clinical trials include an effort to mitigate the risk of treating patients with a known predictably high risk of TdP with drugs that may further prolong the QT interval.

If drugs with the potential to cause ventricular arrhythmia through prolongation of repolarization, including azithromycin, chloroquine, hydroxychloroquine, and lopinavir/ritonavir, are contemplated for treatment of COVID-19, the following precautions should be observed (see [Fig. 1](#fig1){ref-type="fig"} ):•Review medications and discontinue unnecessary medications that may prolong the QT interval.[@bib5]•For patients with known inherited long QT syndrome or a history of drug-induced TdP, use of these drugs should be undertaken only after consultation with a heart rhythm specialist. Potential mitigations could include use of cardiac monitoring or repeated QTc checks. Risk and potential benefit should be individually assessed.•For patients with no history of prolonged QT interval, unexplained syncope, or family history of premature sudden cardiac death and who are not taking other medications that may prolong the QT interval, as well as patients with a previous known normal QTc, it may be reasonable to proceed with antimicrobial drug administration without a baseline or follow-up ECG if obtaining an ECG may increase population risk of infection.•For hospitalized patients, or for those not fulfilling the above criteria:oObtain baseline assessment of:▪ECG to assess QTc if not performed within the past 3 months (see [Fig. 2](#fig2){ref-type="fig"} ).Figure 2How to measure the corrected QT interval (QTc). The QT interval is measured from the onset of the QRS (where it first deviates from baseline) to the intersection of the tangent of the downslope (**dotted green line**) with the baseline (TP segment, **dotted blue line**). This is corrected for heart rate by dividing by the square root of the RR interval, measured in seconds. In the presence of QRS widening (eg, bundle branch block or paced ventricular rhythm), QTc can be adjusted by subtracting the QRS duration (QRSd) that is in excess of 100 ms as in the following formula: $\text{QTc}\left( \text{adjusted} \right)\  = \text{~QTc}\left( \text{measured} \right)\  - \ \left( {\text{QRSd~} - \ 100} \right)$. If the patient is in atrial fibrillation, the QTc interval can be determined from 10 averaged atrial fibrillation beats.▪Electrolytes (Ca^++^, Mg^++^, K^+^) if possible.oIf QTc ≥ 500 ms, reassess after correction of electrolyte abnormalities or discontinuation of other QT interval--prolonging drugs. If QTc remains ≥ 500 ms, seek expert consultation and carefully evaluate benefits and risks.oIf QTc is ≥ 470 ms (male) or QTc is ≥ 480 ms (female), but \< 500 ms, initiate antimicrobial drugs and consider repeated ECG in 48 hours.oIf patients have clinically severe disease or are taking multiple medications that may prolong QT, recheck QTc 48 hours after initiation of antimicrobial drugs.oIf follow-up QTc increases by ≥ 60 ms or is ≥ 500 ms, discontinue the antimicrobial drugs or seek expert consultation. Figure 1Treatment algorithm for COVID-19 therapies that may prolong QT interval. We recommend that the use of these drugs for treating COVID-19 be within evaluative clinical trials. Note that this approach applies during a pandemic and may differ when the population risk of routine testing changes. ∗See [Figure 2](#fig2){ref-type="fig"} for a review of how to measure the QT interval and calculate QTc. ^§^Consider rechecking the QTc interval at 48 hours for inpatients with high risk features (see text) or those with borderline QTc prolongation at baseline. ECG, electrocardiography; QTc, corrected QT interval.

These recommendations are made while there are no known effective treatments for COVID-19 and should be revisited when further data on efficacy and safety become available.
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